Compare KBDC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | CGEM |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 780.4M |
| IPO Year | 2018 | 2020 |
| Metric | KBDC | CGEM |
|---|---|---|
| Price | $13.66 | $16.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $15.50 | ★ $29.89 |
| AVG Volume (30 Days) | 424.4K | ★ 780.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 13.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $8.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.06 | $5.68 |
| 52 Week High | $16.98 | $16.74 |
| Indicator | KBDC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 69.79 |
| Support Level | $13.54 | $6.65 |
| Resistance Level | $15.25 | $16.74 |
| Average True Range (ATR) | 0.35 | 1.04 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 50.60 | 90.36 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.